Frontlight ResearchEarly access
Myeloproliferative neoplasms trials in Japan
11 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Where
- Bunkyo Ku, Chūō, Fukuoka, Kamakura, Kamogawa, Kobe, Kumamoto, Kurashiki, Miyazaki, Sapporo, Shiwa-Gun, Toyoake, Tsu
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07357727 · EU 2025-523555-66-00 - Phase 1Not yet taking people in JapanStudy of INCA036978 in Participants With Myeloproliferative Neoplasms
- Where
- Kashiwa, Chiba, Toon, Ehime
- Age
- 18 years and over
- People
- 218 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07441694 · EU 2026-525217-31-00 - Phase 3Taking peopleA Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- Where
- Bunkyō City, Chūō, Fukuoka, Fukushima, Hirakata, Kagoshima, Kashiwa-shi, Kobe, Miyazaki, Osaka, Sakai, Shinjuku-ku, Tōon, Tsu
- Age
- 18 years and over
- People
- 426 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07623200 · EU 2026-525398-38-00 - Phase 4Active, not recruitingAsciminib Roll-over Study
- Where
- Kobe
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - Phase 3Taking peopleA Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Where
- Bunkyo Ku, Chiba, Chuo-shi, Hitachi, Kobe, Miyazaki, Toon-shi, Tsu
- Age
- 18 years and over
- People
- 324 worldwide
- Run by
- Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00 - Phase 1Taking peopleA Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
- Where
- Bunkyō City, Kashiwa
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06150157 · EU 2023-505584-36-00 - Phase 3Taking peopleINTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
- Where
- Nagasaki, Osaka, Tokyo
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07429266 · EU 2025-524669-25-00 - Phase 1/2Taking peopleA Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Where
- Aichi, Aomori, Chiba, Fukuoka, Hokkaido, Kamakura, Miyazaki, Okayama, Osaka, Saitama, Sendai, Shizuoka, Tokyo, Tsu
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04176198 · EU 2022-502597-16-00 - Phase 2Taking peopleA Study of Rusfertide in Japanese Adults With Polycythemia Vera
- Where
- Bunkyo-ku, Chūō, Maebashi, Miyazaki, Nagoya, Shinjuku-ku, Suita, Sumida-ku, Tsu
- Age
- 18 years and over
- People
- 9
- Run by
- Takeda
See details and how to joinNCT07648030 - Phase 3Taking peopleA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Chiba, Himeji, Hitachi, Kamakura, Kamogawa, Matsuyama, Nagasaki, Nagoya, Ōgaki, Osaka, Sagamihara, Sakai, Sendai, Shibuya City, Shinagawa City
- Age
- 18 years and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - Phase 3Taking peopleExtension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
- Where
- Bunkyo-ku, Chuo-shi, Shinjuku-ku, Suita-shi, Toon-shi, Tsu
- Age
- 20 years and over
- People
- 67
- Run by
- PharmaEssentia Japan K.K.
See details and how to joinNCT04655092